Hong Lü

636 total citations
20 papers, 463 citations indexed

About

Hong Lü is a scholar working on Molecular Biology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Hong Lü has authored 20 papers receiving a total of 463 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 6 papers in Immunology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Hong Lü's work include Heat shock proteins research (5 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Statistical Methods in Clinical Trials (3 papers). Hong Lü is often cited by papers focused on Heat shock proteins research (5 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Statistical Methods in Clinical Trials (3 papers). Hong Lü collaborates with scholars based in United States, Switzerland and Spain. Hong Lü's co-authors include Mark D. Rothmann, Thomas R. Fleming, Mikhail Akimov, Lorin Roskos, Meina Liang, Geoffrey I. Shapiro, Inna Vainshtein, Carolyn D. Britten, Cornelia Quadt and Cristiana Sessa and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Hong Lü

18 papers receiving 441 citations

Peers

Hong Lü
Mirat Shah United States
Jeanne Fourie Zirkelbach United States
Jessica C. Walrath United States
Henry Hiep Vo United States
Corina N.A.M. Oldenhuis Netherlands
Greg Dyson United States
Todd Riehl United States
Lina Pugliano Belgium
John H. Moon United States
Vegard Nygaard Norway
Mirat Shah United States
Hong Lü
Citations per year, relative to Hong Lü Hong Lü (= 1×) peers Mirat Shah

Countries citing papers authored by Hong Lü

Since Specialization
Citations

This map shows the geographic impact of Hong Lü's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hong Lü with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hong Lü more than expected).

Fields of papers citing papers by Hong Lü

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hong Lü. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hong Lü. The network helps show where Hong Lü may publish in the future.

Co-authorship network of co-authors of Hong Lü

This figure shows the co-authorship network connecting the top 25 collaborators of Hong Lü. A scholar is included among the top collaborators of Hong Lü based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hong Lü. Hong Lü is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Hu, Wentao, Menghan Wang, Guifang Sun, Limin Zhang, & Hong Lü. (2024). RND3 modulates microglial polarization and alleviates neuroinflammation in Parkinson's disease by suppressing NLRP3 inflammasome activation. Experimental Cell Research. 439(1). 114088–114088. 2 indexed citations
3.
4.
Lü, Hong, Zhigang Yu, Cheng‐Pang Hsu, et al.. (2020). Pharmacokinetic/pharmacodynamic and safety study of a single dose of evolocumab 140 mg in healthy Chinese subjects. International Journal of Clinical Pharmacology and Therapeutics. 58(10). 557–564.
5.
Kumar, Vipul, Hong Lü, Marjie Hard, & Lisa Von Moltke. (2019). Characterization of the Pharmacokinetics of Samidorphan in Healthy Volunteers: Absolute Bioavailability and the Effect of Food and Age. Drugs in R&D. 19(3). 277–287. 8 indexed citations
6.
Pathak, Sanjeev, Bradley Vince, Debra Kelsh, et al.. (2018). Abuse Potential of Buprenorphine/Samidorphan Combination Compared to Buprenorphine and Placebo: A Phase 1 Randomized Controlled Trial. The Journal of Clinical Pharmacology. 59(2). 206–217. 8 indexed citations
7.
Thompson, Laura, Sherry Liu, Hong Lü, et al.. (2016). Adaptive Design Practice at the Center for Devices and Radiological Health (CDRH), January 2007 to May 2013. Therapeutic Innovation & Regulatory Science. 50(6). 710–717. 12 indexed citations
8.
Roman, Danielle, James N. Ver Hoeve, Heiko S. Schadt, et al.. (2016). Ocular toxicity of AUY922 in pigmented and albino rats. Toxicology and Applied Pharmacology. 309. 55–62. 5 indexed citations
9.
Spreafico, Anna, J.P. Delord, Leticia De Mattos‐Arruda, et al.. (2015). A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies. British Journal of Cancer. 112(4). 650–659. 27 indexed citations
10.
Seggewiss‐Bernhardt, Ruth, Ralf C. Bargou, Yeow Tee Goh, et al.. (2015). Phase 1/1B trial of the heat shock protein 90 inhibitor NVP‐AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. Cancer. 121(13). 2185–2192. 52 indexed citations
11.
Ryan, Patricia C., Matthew A. Sleeman, Marlon C. Rebelatto, et al.. (2014). Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: Relevance for human safety. Toxicology and Applied Pharmacology. 279(2). 230–239. 14 indexed citations
12.
Sessa, Cristiana, Geoffrey I. Shapiro, Kapil N. Bhalla, et al.. (2013). First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors. Clinical Cancer Research. 19(13). 3671–3680. 119 indexed citations
13.
Mattos‐Arruda, Leticia De, Lillian L. Siu, Javier Cortés, et al.. (2013). Phase I dose-escalation, open-label study of HSP990 administered orally in adult patients with advanced solid malignancies.. Journal of Clinical Oncology. 31(15_suppl). 2561–2561. 4 indexed citations
14.
Wang, Bing, Yvonne Lau, Meina Liang, et al.. (2011). Mechanistic Modeling of Antigen Sink Effect for Mavrilimumab Following Intravenous Administration in Patients With Rheumatoid Arthritis. The Journal of Clinical Pharmacology. 52(8). 1150–1161. 24 indexed citations
15.
Roskos, Lorin, Amy Schneider, Inna Vainshtein, et al.. (2011). PK–PD Modeling of Protein Drugs: Implications in Assay Development. Bioanalysis. 3(6). 659–675. 36 indexed citations
16.
Tabrizi, Mohammad, Bing Wang, Hong Lü, et al.. (2010). Population Pharmacokinetic Evaluation of a Fully Human IgG2 Monoclonal Antibody in Patients with Inflammatory Diseases. Inflammation & Allergy - Drug Targets. 9(4). 229–237. 13 indexed citations
17.
Rothmann, Mark D., Kallappa M. Koti, Kyung‐Yul Lee, Hong Lü, & Yuan Li Shen. (2009). Missing Data in Biologic Oncology Products. Journal of Biopharmaceutical Statistics. 19(6). 1074–1084. 2 indexed citations
18.
Fleming, Thomas R., Mark D. Rothmann, & Hong Lü. (2009). Issues in Using Progression-Free Survival When Evaluating Oncology Products. Journal of Clinical Oncology. 27(17). 2874–2880. 131 indexed citations
19.
Sayar, Hamid, Zhiyuan Shen, Melanie Royce, et al.. (2008). Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies. Investigational New Drugs. 27(2). 153–158. 1 indexed citations
20.
Lü, Hong & Mohammad F. Huque. (2001). Understanding on the Pooled Test for Controlled Clinical Trialsn. Biometrical Journal. 43(7). 909–923. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mirat Shah Breakdown of academic impact, for papers by Jeanne Fourie Zirkelbach Breakdown of academic impact, for papers by Jessica C. Walrath Breakdown of academic impact, for papers by Henry Hiep Vo Breakdown of academic impact, for papers by Corina N.A.M. Oldenhuis Breakdown of academic impact, for papers by Greg Dyson Breakdown of academic impact, for papers by Todd Riehl Breakdown of academic impact, for papers by Lina Pugliano Breakdown of academic impact, for papers by John H. Moon Breakdown of academic impact, for papers by Vegard Nygaard
Rankless by CCL
2026